The Nephroprotective Effect of TNF Receptor-Associated Factor 6 (TRAF6) Blockade on LPS-Induced Acute Renal Injury Through the Inhibition if Inflammation and Oxidative Stress.


Journal

Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063

Informations de publication

Date de publication:
13 01 2020
Historique:
entrez: 14 1 2020
pubmed: 14 1 2020
medline: 8 10 2020
Statut: epublish

Résumé

BACKGROUND Inflammation and oxidative stress play important roles in the pathogenesis of acute kidney injury (AKI). TRAF6 functions as a signal transducer in the Toll-like receptor 4 signaling pathway. Several reports have previously implicated TRAF6 signaling in kidney pathology. Here, we investigated whether TRAF6 blockade can mitigate inflammatory responses and oxidative stress in AKI. MATERIAL AND METHODS C57BL/6 mice were injected with lipopolysaccharide (LPS, 15 mg/kg) to induce AKI. Double immunofluorescence staining of kidney tissues showed that TRAF6 was localized to renal tubular epithelial cells, and then a tubular epithelial cell line (NRK-52E) was used for in vitro analysis. TRAF6 was blocked in vitro using siRNA and in vivo using AAV2/2 shRNA. RESULTS The knockdown of TRAF6 in mice by AAV2-shTRAF6 significantly reduced renal inflammation, oxidative stress, apoptosis and kidney dysfunction in AKI. In vitro, silencing the expression of TRAF6 attenuated LPS(0.5 μg/mL)-induced inflammatory responses and oxidative stress and upregulated proapoptotic factors. Furthermore, the beneficial actions of TRAF6 blockade were closely associated with its ability to increase IkappaB-alpha and Nrf2. CONCLUSIONS Our findings provide direct evidence that TRAF6 mediates LPS-induced inflammation and oxidative stress, leading to renal dysfunction. We also show that TRAF6 inhibition is a potential therapeutic option to prevent AKI.

Identifiants

pubmed: 31929494
pii: 919698
doi: 10.12659/MSM.919698
pmc: PMC6977635
doi:

Substances chimiques

Lipopolysaccharides 0
NF-E2-Related Factor 2 0
Nfe2l2 protein, mouse 0
Protective Agents 0
RNA, Small Interfering 0
TNF Receptor-Associated Factor 6 0
NF-KappaB Inhibitor alpha 139874-52-5

Types de publication

Journal Article Retracted Publication

Langues

eng

Sous-ensembles de citation

IM

Pagination

e919698

Commentaires et corrections

Type : RetractionIn

Références

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):500-14
pubmed: 25376763
Acta Physiol (Oxf). 2010 Jul 1;199(3):339-46
pubmed: 20136795
Hypertension. 2018 Dec;72(6):1301-1311
pubmed: 30571233
Transplantation. 2013 Mar 15;95(5):653-7
pubmed: 23503499
Clin J Am Soc Nephrol. 2011 Jul;6(7):1744-51
pubmed: 21734090
Sci Rep. 2019 Apr 15;9(1):6044
pubmed: 30988361
Clin Exp Pharmacol Physiol. 2013 Jan;40(1):53-5
pubmed: 23216315
Mol Nutr Food Res. 2016 Dec;60(12):2665-2677
pubmed: 27466783
Mutat Res. 2010 Aug 7;690(1-2):12-23
pubmed: 19799917
Ulster Med J. 2014 Sep;83(3):149-57
pubmed: 25484464
Immunol Rev. 2015 Jul;266(1):72-92
pubmed: 26085208
Kidney Int. 1995 Sep;48(3):674-82
pubmed: 7474651
Mol Neurobiol. 2013 Aug;48(1):190-204
pubmed: 23436141
Nephron Exp Nephrol. 2008;109(4):e109-17
pubmed: 18802373
Inflammation. 2019 Apr;42(2):637-649
pubmed: 30392071
Biomed Pharmacother. 2017 Jan;85:704-711
pubmed: 27923689
Shock. 2014 Jan;41(1):3-11
pubmed: 24346647
Clin Exp Nephrol. 2009 Feb;13(1):9-14
pubmed: 19085040
Kidney Int. 2000 May;57(5):2011-22
pubmed: 10792620
Crit Care. 2016 Mar 15;20:61
pubmed: 26976392
Kidney Int. 2011 Feb;79(3):288-99
pubmed: 20927041
Biomed Pharmacother. 2019 Sep;117:109070
pubmed: 31176164
Bioorg Med Chem. 2013 Jul 15;21(14):4011-9
pubmed: 23647822
Drug Des Devel Ther. 2018 Nov 22;12:3985-3997
pubmed: 30538426
Mediators Inflamm. 2009;2009:137072
pubmed: 20182538
Environ Health Perspect. 2002 Oct;110 Suppl 5:819-22
pubmed: 12426138

Auteurs

Xuemei Chen (X)

Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).

Yiqing Zhao (Y)

Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).

Jiajun Xu (J)

Department of Cardiology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China (mainland).

Jiachun Bao (J)

Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).

Junyao Zhao (J)

Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).

Jingfeng Chen (J)

Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China (mainland).

Guowei Chen (G)

Department of Cardiology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China (mainland).

Jibo Han (J)

Department of Cardiology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China (mainland).

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH